Effects of cancer drugs on survival: often poorly evaluated.
(1) Overall survival is the gold-standard endpoint when evaluating the efficacy of cancer drugs; (2) Progression-free survival is an endpoint that combines two very different components: death or objective worsening of the tumour. It is a heterogeneous endpoint and measurement of the second component is imprecise. There are few examples where a correlation has been established between progression-free survival and overall survival; (3) Time to progression is an endpoint of limited interest: it only takes into account the second component of the progression-free survival composite endpoint; (4) Disease-free survival is a variant of progression-free survival and is most frequently used for adjuvant treatments.